苏黄止咳胶囊治疗慢性阻塞性肺疾病急性发作期的临床疗效及长期随访观察

发布时间：2018-04-24 22:41

本文选题：慢性阻塞性肺疾病 + 苏黄止咳胶囊　；参考：《辽宁中医杂志》2017年06期

【摘要】：目的:探讨苏黄止咳胶囊治疗慢性阻塞性肺疾病急性发展期的临床疗效以及长期随访结果。方法:选取2014年1月—2015年6月来本院治疗的107例老年慢阻肺患者为研究对象,随机分为治疗组和对照组,其中治疗组53例,对照组54例。对照组患者给予常规治疗,治疗组患者在常规治疗的基础上,给予每天口服苏黄止咳胶囊,3粒/次,3次/d,4周为1个疗程。在疗程结束后,进行12个月以上的随访观察。结果:随访期间,治疗组与对照组比较,急性加重次数和再入院率明显降低(P0.01);治疗组的第一秒用力呼气量占预计值百分比(FEV1)、第一秒用力呼气量/用力肺活量(FEV1/FVC)均明显升高,残气量(RV)、残气与肺总量比值(RV/TLC)均明显降低,与治疗前和对照组比较,差异均具有统计学意义(P0.05);另外,治疗组的生存质量评估表得分明显降低,6 min步行距离明显提高,与治疗前和对照组相比较,差异均具有统计学意义(P0.05)。结论:苏黄止咳胶囊口服可以改善慢性阻塞性肺病患者的肺功能,提高生存质量,减少慢性阻塞性肺病急性加重和再入院次数。
[Abstract]:Objective: to investigate the clinical effect and long-term follow-up of Suhuang Zhike capsule in the treatment of chronic obstructive pulmonary disease (COPD). Methods: 107 elderly patients with COPD treated in our hospital from January 2014 to June 2015 were randomly divided into treatment group (53 cases) and control group (54 cases). The patients in the control group were given routine treatment, and the patients in the treatment group were given three capsules of Suhuang Zhike capsule every day for 4 weeks as a course of treatment. At the end of the course of treatment, more than 12 months of follow-up observation. Results: during the follow-up period, the times of acute exacerbation and readmission rate in the treatment group were significantly lower than those in the control group, and the percentage of forced expiratory volume in the first second and FEV1 / FEV1 / FEV1 / FEV 1 / FVC in the treatment group were significantly higher than those in the control group, and the first second forced expiratory volume / forced vital capacity and FEV 1 / FVC were significantly higher in the treatment group than in the control group. The RV / TLC ratio and the ratio of residual gas to lung volume were significantly decreased, compared with those before treatment and control group, the difference was statistically significant (P 0.05), in addition, the score of QOL in the treatment group was significantly lower than that in the control group, and the walking distance of 6 min in the treatment group was significantly lower than that in the control group, and the score of RV / TLC in the treatment group was significantly lower than that in the control group. The difference was statistically significant compared with that before treatment and control group (P 0.05). Conclusion: Su Huang Zhike capsule can improve pulmonary function, improve quality of life and reduce acute exacerbation and readmission of chronic obstructive pulmonary disease.
【作者单位】：天津市滨海新区大港医院;
【分类号】：R563.9

【相似文献】